LRPPRC (leucine rich pentatricopeptide repeat containing) specific nucleic acid aptamer and application thereof
A nucleic acid aptamer and nucleic acid aptamer technology, applied in the field of medicine, can solve the problems of unclear LRPPRC target effect and treatment mechanism, and achieve the effects of enhanced killing effect, enhanced therapeutic effect, and good tissue permeability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0041] Embodiment 1, the synthesis of nucleic acid aptamer and its pretreatment
[0042]Nucleic acid aptamer R14 without any modification: 5'-GGTGGGTGGGTTGGGTGG-3' (SEQ ID NO: 1, wherein G and T represent unmodified guanine and thymine, respectively). Synthesized by AB 3400 DNA synthesizer, the synthesized DNA was purified by HPLC, vacuum-dried, 80% acetic acid to remove DMT, ethanol precipitation and vacuum-dried, adjusted to pH 7.0 with Tris-HCl (pH 9.0), filtered and sterilized, and finally used without Bacteria were diluted to 500 μM in D-PBS and stored at -20°C for later use.
Embodiment 2
[0043] Example 2, the growth of nucleic acid aptamer R14 on A549 and A973 cells in vitro
[0044] After A549 cell-grade A973 cells were treated with trypsin-EDTA and centrifuged, they were planted in a 96-well plate of xCELLigence RTCA MP system label-free cell function analyzer at a density of 2000 cells / well and cultured for 24 hours. The fresh medium containing LRPPRC-specific nucleic acid aptamer R14 was replaced with a concentration gradient of 5 μM, 10 μM, 20 μM, 40 μM, or negative control sequence RTT (40 μM), and cultured for 24 h. For each treatment, 6 groups of parallel experiments were set up. Cultivate and test, draw cell growth rate curve, see results figure 1 . Experiments show that the aptamer R14 can significantly inhibit the growth of lung cancer A549 and A973 in vitro, and the effect is concentration-gradient dependent.
Embodiment 3
[0045] Example 3. Influence of nucleic acid aptamer R14 combined with SRC kinase inhibitor on the proliferation of A549 and A973 cells in vitro
[0046] After A549 cells and A973 cells were treated with trypsin-EDTA and centrifuged, they were planted in a 96-well plate of xCELLigence RTCA MP system label-free cell function analyzer at a density of 2000 cells / well and cultured for 24 hours. Replace with fresh medium containing LRPPRC-specific nucleic acid aptamer R14 or an irrelevant control sequence at a concentration of 5 μM, and culture for 24 hours. Add the corresponding SRC kinase inhibitor, continue to culture and detect, set 6 groups of parallel experiments for each group of treatments, see the results figure 2 . Experiments have shown that 5 μM aptamer R14 can significantly increase the sensitivity of lung cancer A549 and A973 to SRC kinase in vitro, and the combination of the two can effectively kill tumor cells.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com